- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03077763
The Haem and Nitrite Study - The Effects of Haemoglobin NO-blockade on Nitrite-induced Forearm Vessel Dilatation
The Effects of Free Haemoglobin NO-blockade on Nitrite Forearm Vessel Dilatation Under Normoxia and Hypoxia in Healthy Volunteers
Studieoversikt
Detaljert beskrivelse
This is a healthy volunteer study.
Following entry into this cross-over trial, participants will be randomized to undergo experiments under either normoxic followed by hypoxic conditions, or hypoxic followed by normoxic conditions.
Subjects will donate whole blood as an autologous unit at a preselected NHSBT donation site. The unit will transported back to the NNUH blood bank after a minimum of 30 days (maximum 35 days) after donation.
Volunteers will be tested for baseline bloods. Volunteers will be randomised to normoxia or hypoxia. The will then undergo a nitrite infusion, followed by an autologous whole blood transfusion and a second nitrite infusion (which will co-infuse at the end of the transfusion). During the protocol, the participants will undergo repeated FBFR measurements using strain-gauge plethysmography.
After a minimum of 12 weeks rest period after their initial donation, participants will cross-over to the opposite oxygen condition (as per initial randomization) and the above protocol will be repeated. All interventions will be performed by fully trained and competent medical staff.
Studietype
Registrering (Forventet)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Norfolk
-
Norwich, Norfolk, Storbritannia, NR4 7UQ
- Rekruttering
- University of East Anglia
-
Ta kontakt med:
- Nicholas D Gollop, MRCP
- Telefonnummer: 1790 01603 591790
- E-post: n.gollop@uea.ac.uk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female, aged greater than or equal to 18 years
- If between 18-20 years of age, calculate total blood volume should be more than >3.5L (http://www.blood.co.uk/giving-blood/who-can-give-blood/)
- Body weight > 50kg weight (8 stone 12lbs)
- Not known to have any significant past medical history and not having regular follow up (Check Donor Selection Guidelines (http://www.transfusionguidelines.org.uk/)
- Willing to provide blood donation and receive autologous blood transfusion
- After assessment for eligibility pass all blood donor eligibility criteria
- Able to provide informed consent
- Should inform overseas travel plan during study period (Check Geographical Disease Risk Index on http://www.transfusionguidelines.org.uk/dsg/gdri) e.g. unable to donate blood for 6 months if travel in a malaria endemic country. Similar guidelines for West Nile virus and T. Cruzi endemic countries.
Exclusion Criteria:
- Significant medical, surgical or psychiatric disease that in the opinion of the Clinical Research Fellow would affect subject safety or significantly impact his/her ability to comply with follow-up. This would include any known clotting disorders.
- Known allergy or intolerance to Nitrites
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Female subjects must be of non-childbearing potential, defined as follows: postmenopausal females who have had at least 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhoea with serum FSH>40mIU/ml or females who have had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy at least 6 weeks prior to enrolment
- Receipt of an investigational drug or biological agent within the 4 weeks prior to study entry or 5 times the drug half-life, whichever is the longer
- Predisposed to acute on chronic limb ischemia evident from a history of claudication or known peripheral arterial disease.
- No past history of significant adverse events post blood donation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Normoxia and Nitrite (3umol/min-1)
Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence.
Normoxia (3umol/min-1).
|
|
Aktiv komparator: Hypoxia and Nitrite (1umol/min-1)
This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in FBFR during intra-brachial nitrite and haemolysed blood co-infusion in normoxia vs hypoxia.
Tidsramme: Up to 18 months
|
Up to 18 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in FBFR during haemolysed blood infusion vs baseline
Tidsramme: Up to 18 months
|
Up to 18 months
|
Change in FBFR during nitrite infusion in normoxia vs nitrite infusion in hypoxia
Tidsramme: Up to 18 months
|
Up to 18 months
|
Change in FBFR during nitrite infusion in normoxia vs baseline
Tidsramme: Up to 18 months
|
Up to 18 months
|
Change in FBFR during nitrite infusion in hypoxia vs baseline
Tidsramme: Up to 18 months
|
Up to 18 months
|
Blood analysis (cell free haemoglobin, nitrate, nitrite and nitroso species levels)
Tidsramme: Up to 18 months
|
Up to 18 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Michael P Frenneaux, FRCP, FESC, Dean of Medicine, Norwich Medical School, The University of East Anglia, UK
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 206995
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Friske Frivillige
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på Natriumnitritt
-
Beijing Tiantan HospitalHar ikke rekruttert ennåØdem hjerne
-
University of PennsylvaniaNational Institute on Aging (NIA)Rekruttering
-
Novartis PharmaceuticalsFullførtForhøyet kolesterol | Homozygot familiær hyperkolesterolemi | Heterozygot familiær hyperkolesterolemi | ASCVDForente stater, Canada, Tsjekkia, Danmark, Tyskland, Ungarn, Nederland, Polen, Sør-Afrika, Spania, Sverige, Ukraina, Storbritannia
-
AstraZenecaFullførtEn studie for å undersøke sikkerheten og effekten av ZS hos pasienter med hyperkalemi (HARMONIZE GL)HyperkalemiKorea, Republikken, Taiwan, Den russiske føderasjonen, Japan
-
Beijing Chao Yang HospitalRekrutteringSubkliniske hypotyreoseKina
-
Retina Institute of HawaiiEyetech PharmaceuticalsTilgjengeligDiabetisk makulært ødemForente stater
-
Retina Institute of HawaiiFullført
-
AstraZenecaRekrutteringHyperkalemiKina, Tyskland, Forente stater, Ukraina, Spania, Japan, Storbritannia, Canada, Polen, Romania, Den russiske føderasjonen, Brasil
-
Eli Lilly and CompanyRekrutteringForhøyet Lp(a) | Aterosklerotisk kardiovaskulær sykdom (ASCVD)Forente stater, Australia, Belgia, Spania, Japan, Canada, Argentina, Kina, Italia, Nederland, Frankrike, Tyskland, Taiwan, Korea, Republikken, Brasil, Danmark, Ungarn, Israel, Østerrike, Mexico, Romania, Storbritannia, Hellas, Polen, Tsje... og mer